Found: 14
Select item for more details and to access through your institution.
Monoclonal antibodies and autologous stem cell transplantation for lymphoma.
- Published in:
- Bone Marrow Transplantation, 2001, v. 27, n. 6, p. 565, doi. 10.1038/sj.bmt.1702857
- By:
- Publication type:
- Article
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.
- Published in:
- Leukemia (08876924), 2012, v. 26, n. 10, p. 2197, doi. 10.1038/leu.2012.134
- By:
- Publication type:
- Article
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.
- Published in:
- Leukemia (08876924), 2012, v. 26, n. 10, p. 2302, doi. 10.1038/leu.2012.175
- By:
- Publication type:
- Article
ZUMA‐22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL (AXI‐CEL) VS STANDARD‐OF‐CARE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 853, doi. 10.1002/hon.3166_OT31
- By:
- Publication type:
- Article
ZUMA‐24: A PHASE 2, OPEN‐LABEL STUDY OF AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA GIVEN OUTPATIENT WITH CORTICOSTEROIDS.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 843, doi. 10.1002/hon.3166_OT23
- By:
- Publication type:
- Article
ZUMA‐23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST‐LINE THERAPY IN PATIENTS WITH HIGH‐RISK LARGE B‐CELL LYMPHOMA.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 171, doi. 10.1002/hon.3163_T06
- By:
- Publication type:
- Article
RADIOMICS REFLECTING BOTH TUMOR AND HOST FEATURES IMPROVES OUTCOME PREDICTION IN FOLLICULAR LYMPHOMA.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 94, doi. 10.1002/hon.3163_58
- By:
- Publication type:
- Article
Updated follow‐up of BELLWAVE‐001: an open‐label, single‐arm, phase 1/2 study of the efficacy and safety of nemtabrutinib for the treatment of B‐cell malignancies.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 565, doi. 10.1002/hon.3164_423
- By:
- Publication type:
- Article
A phase 2 study of zanubrutinib in previously treated B‐cell malignancies intolerant to ibrutinib and/or acalabrutinib: Preliminary results for patients with CLL/SLL.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 469, doi. 10.1002/hon.3164_345
- By:
- Publication type:
- Article
Ibrutinib (Ibr) dose modification for management of early cardiac adverse events in patients with chronic lymphocytic leukemia: Pooled analysis of 7 clinical trials.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 461, doi. 10.1002/hon.3164_340
- By:
- Publication type:
- Article
Outpatient administration of mosunetuzumab in US community practice settings: perspectives and learnings from the Phase II MorningSun study.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 383, doi. 10.1002/hon.3164_278
- By:
- Publication type:
- Article
ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT‐NAïVE (TN) CLL/SLL: EXTENDED FOLLOW‐UP OF THE SEQUOIA STUDY.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 235, doi. 10.1002/hon.3163_154
- By:
- Publication type:
- Article
Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.
- Published in:
- Leukemia (08876924), 2005, v. 19, n. 7, p. 1207, doi. 10.1038/sj.leu.2403782
- By:
- Publication type:
- Article
Highlights in Chronic Lymphocytic Leukemia.
- Published in:
- Clinical Advances in Hematology & Oncology, 2013, v. 11, p. 2
- By:
- Publication type:
- Article